Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsTranslating TrialsCase-Based Peer PerspectivesPodcastsVideosShorts
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Yuhong Dong, MD, PhD

Advertisement

Articles by Yuhong Dong, MD, PhD

Yuhong Dong on the Benefits of Falun Gong for Patients With Terminal Cancer

ByYuhong Dong, MD, PhD
August 4th 2016

Yuhong Dong, MD, PhD, clinical researcher at Novartis, discusses the benefits of practicing Falun Gong for patients with terminal cancer.

Advertisement

Latest Updated Articles

  • Yuhong Dong on the Benefits of Falun Gong for Patients With Terminal Cancer
    Yuhong Dong on the Benefits of Falun Gong for Patients With Terminal Cancer

    August 4th 2016



Advertisement
Advertisement

Trending on Oncology Nursing News

1

FDA Camizestrant Approval: Nurses Key to New Breast Cancer Paradigm

2

Nursing Protocols for the New Oral RAS Inhibitor Daraxonrasib

3

FDA Approves Iberdomide: A New Oral Paradigm in Multiple Myeloma Care

4

How the Emerging MPN Pipeline Will Reshape PV Nursing and Patient Care

5

FDA Approves Camizestrant for ESR1-Mutated Advanced Breast Cancer

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us